Join us at #MDedgeChats on Tuesday, April 23, 2019, at 7:00 pm EST, for a discussion in Rheumatology on some of the top studies reported at the LUPUS 2019 Congress in San Francisco, April 5-8. Our special guests are two rheumatologists with expertise in lupus who attended the congress, , and , both with the University of California, San Francisco. They will discuss the ins and outs of the study results presented.
We hope you can join us and invite a colleague, too.
We will discuss the results of the EMBRACE trial, which looks at the efficacy and safety of belimumab (Benlysta) in black patients with systemic lupus erythematosus (SLE); these patients have a higher prevalence of SLE and often higher disease severity but have been poorly represented in past belimumab studies.
We will also chat about the results of a phase 2 trial of baricitinib (Olumiant) in SLE patients.
Finally, we will look at the clinical utility of monitoring hydroxychloroquine levels in SLE patients and how well levels of the drug correlate with disease activity through the results of a meta-analysis of studies that examined these questions.
Topics of conversation
Q1: How does the methodology of the EMBRACE trial differ from past phase 3 belimumab trials?
Q2: How does the EMBRACE trial affect the way you prescribe belimumab?
Q3: Does the hydroxychloroquine level meta-analysis provide persuasive enough evidence to begin measuring it?
Q4: What kinds of interventions show the best evidence for improving hydroxychloroquine adherence?
Q5: Were concerns about the safety of baricitinib in SLE patients reduced by the trial results?
EMBRACE trial: Efficacy and Safety of Belimumab in Black Race Patients with Systemic Lupus Erythematosus.
Phase 2 trial of baricitinib in SLE.
Meta-analysis examining the clinical significance of monitoring of hydroxychloroquine levels in SLE.
From LUPUS 2019:
From EULAR 2018:
About Dr. Yazdany
Dr. Yazdany is an associate professor in the division of rheumatology, department of medicine at UCSF (
About Dr. Schmajuk
Dr. Schmajuk is an Associate Professor in the Division of Rheumatology, Department of Medicine at UCSF () and the San Francisco VA Medical Center. She is a rheumatologist and clinical researcher with expertise in systemic #lupus erythematosus, quality of care, and patient safety. Dr. Schmajuk also co-directs the Quality and Informatics Lab ( ), which uses data to drive improvements in health care delivery and outcomes for people with rheumatic diseases. She leads studies to develop patient-facing disease dashboards with the goal of improving patient-provider communication for patients with RA and SLE.
Are you new to Twitter chats? We have included simple steps below to help you join and participate in the conversation.